We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01670955
Recruitment Status : Completed
First Posted : August 23, 2012
Last Update Posted : May 18, 2016
Health Forever Product Limited. Lagos, Nigeria
Information provided by (Responsible Party):
Dr. A. Tayo, Lagos State University

Brief Summary:

Condition or disease Intervention/treatment Phase
Anemia Dietary Supplement: Jobelyn Drug: Ferrous Sulphate + Folic Acid Phase 2

Detailed Description:

It has long been known that anaemia increases the risk of death and complications in patients who have cardiovascular surgery, but results of a recent study show that these risks are increased in patients with anaemia who undergo various types of surgery, including gynaecological procedures.

Compared with patients without anaemia, the risk of death within 30 days after surgery was 42% higher among patients with anaemia. In addition, patients with anemia were 35% more likely to experience cardiac, respiratory, urinary, and wound complications as well as sepsis and blood clots.

Because even mild anaemia increases the risk of postoperative morbidity in patients undergoing major non-cardiac surgery, doctors need to consider preoperative treatment of anaemia when possible. More research is needed to establish the efficacy, safety and cost-effectiveness of pre-operative anaemia management.

One of the major clinical issues in many gynaecological patients in Nigeria is that of optimizing the packed cell volume before surgery. Anaemia could be traced to multiple factors notable of which are high prevalence of infection, worm infestation and malnutrition (R). In other to reduce the waiting time and reduce morbidity and mortality associated with surgery, it is important to correct the packed cell volume adequately before surgery.

The traditional method of correcting PCV involves the use of 'routine' haematinics such as Ferrous sulphate, Folic acid and Multivitamin. This is in addition to dietary advice. While the efficacy of these drugs has been well acknowledged in clinical practice, there is dearth of literatures on their specific influence on haematological parameters. Majority of Nigerians are gradually having a change of perception about traditional medicines with gradual shift towards their use. It is believed that traditional drugs act faster and more effective than other orthodox drugs in conventional use. One of such area is in the correction of anaemia.

Sorghum bicolor, a grain long used in Africa for its high nutritional value also exhibits strong antioxidant properties and antiinflammatory effects. The traditional preparation of Sorghum bicolor has an oxygen radical absorbance capacity (ORAC) OF 37,622 micro mole TE/g. This is much higher than other botanical preparations. Complementing the antioxidant properties, Sorghum bicolor also exhibits anti inflammatory effects and demonstrated selective COX-2 inhibition, providing effective reduction in inflammation without residual side effects.

Sorghum bicolor extract has been shown to increase the haematocrit and haemoglobin level and reduce the white cell count in trypanosome brucei brucei induced anaemia in experimental rabbits. These effects were conclusive within 49 days of experimentation. Animals sacrificed after the administration of lethal dose Jobelyn were shown to have congestion of the liver, kidneys and lungs. This might be as a result of direct effect on these organs or a sign of cardiotoxicity. However there is a wide therapeutic range.

Sorghum bicolor is the proprietary name for the product intended to treat sickle cell disease. It is exactly the same as jobelyn which is currently marketed as a nutritional supplement. Jobelyn is marketed in 250mg capsules of sorghum bicolor leaf extract. The product is widely marketed in the United States and in Nigeria. Many pregnant women have been using it regularly for a long time without any report of adverse effect.

The sorghum bicolor extract is expected to increase the haematocrit of' pregnant women within a short time.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Prospective Phase II/III Randomized, Blinded Study to Demonstrate the Safety and Effectiveness of Jobelyn ( a Herbal Preparation ) in Pre-operative Management of Anaemia in Gynaecological Patients
Study Start Date : December 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Active Comparator: Jobelyn + Ferrous Sulphate + Folic Acid
Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
Dietary Supplement: Jobelyn
Jobelyn is a sorghum bicolor extract marketed as dietary supplement
Other Name: Sorghum bicolor extract

Drug: Ferrous Sulphate + Folic Acid
Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Other Name: Iron Tablets

Active Comparator: Ferrous Sulphate + Folic Acid
Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Drug: Ferrous Sulphate + Folic Acid
Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Other Name: Iron Tablets

Primary Outcome Measures :
  1. Anaemia [ Time Frame: 3 months ]
    Change in haematological parameters

Secondary Outcome Measures :
  1. morbidity [ Time Frame: 3 months ]
    Reduced postoperative morbidity

Other Outcome Measures:
  1. Hospital Stay [ Time Frame: 3 months ]
    Duration of hospital stay

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Mild to moderate anaemia
  • Asymptomatic severe anaemia
  • Non life threatening gynaecological condition

Exclusion Criteria:

  • Failure to give informed consent
  • Symptomatic severe anaemia
  • Pregnancy
  • Malignancies and Chronic inflammatory disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01670955

Layout table for location information
Lagos State University Teaching Hospital
Ikeja, Lagos, Nigeria, 100001
Sponsors and Collaborators
Lagos State University
Health Forever Product Limited. Lagos, Nigeria
Layout table for investigator information
Principal Investigator: Adetokunbo O Tayo, M.D. Lagos State University

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT01670955    
Other Study ID Numbers: LASUTH/08/2012
First Posted: August 23, 2012    Key Record Dates
Last Update Posted: May 18, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Dr. A. Tayo, Lagos State University:
gynecological patients
Sorghum bicolor
Packed Cells Volume
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases
Folic Acid
Vitamin B Complex
Physiological Effects of Drugs